Replimune Group (Replimune Group) Marketable Securities : $346.21 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Replimune Group Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Replimune Group's Marketable Securities for the quarter that ended in Mar. 2024 was $346.21 Mil.

Replimune Group's annual Marketable Securities increased from Mar. 2022 ($289.71 Mil) to Mar. 2023 ($436.80 Mil) but then declined from Mar. 2023 ($436.80 Mil) to Mar. 2024 ($346.21 Mil).

Replimune Group Marketable Securities Historical Data

The historical data trend for Replimune Group's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replimune Group Marketable Securities Chart

Replimune Group Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Marketable Securities

Get a 7-Day Free Trial

109.06

293.78

289.71

436.80

346.21

Replimune Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															436.80	432.62	420.77	368.68	346.21

Replimune Group Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Replimune Group (NAS:REPL) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Replimune Group Marketable Securities Related Terms

Thank you for viewing the detailed overview of Replimune Group's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Replimune Group (Replimune Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Replimune Group Inc (NAS:REPL) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

7R8:Germany

Address

500 Unicorn Park Drive, Suite 303, Woburn, MA, USA, 01801

Website

https://www.replimune.com

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Executives

Christopher Sarchi	officer: Chief Commercial Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Konstantinos Xynos	officer: Chief Medical Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Emily Luisa Hill	officer: Chief Financial Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pamela Esposito	officer: Chief Business Officer	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Sushil Patel	officer: Chief Commercial Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Tanya Lewis	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Veleka Peeples-dyer	director	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Andrew Schwendenman	officer: Chief Accounting Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Philip Astley-sparke	director, 10 percent owner, officer: Executive Chairman	C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Robert Coffin	director, 10 percent owner, officer: President and C.E.O.	C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Love Colin	10 percent owner, officer: Chief Operating Officer	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 10801
Jean M. Franchi	officer: Chief Financial Officer	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Omega Fund Iv Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Jason P Rhodes	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139